Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells
出版年份 2018 全文链接
标题
Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells
作者
关键词
-
出版物
CANCER BIOLOGY & THERAPY
Volume -, Issue -, Pages 1-10
出版商
Informa UK Limited
发表日期
2018-09-28
DOI
10.1080/15384047.2018.1504718
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Hypermutation In Pancreatic Cancer
- (2017) Jeremy L. Humphris et al. GASTROENTEROLOGY
- Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma
- (2017) Michael E Feigin et al. NATURE GENETICS
- Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer
- (2017) Changwen Ning et al. Oncotarget
- Molecular Pathways Controlling Autophagy in Pancreatic Cancer
- (2017) Maria New et al. Frontiers in Oncology
- Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent
- (2016) Emma J. Haagensen et al. EUROPEAN JOURNAL OF CANCER
- PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
- (2016) Vivek Asati et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Reduced PDCD4 Expression Promotes Cell Growth Through PI3K/Akt Signaling in Non-Small Cell Lung Cancer
- (2016) Yan Zhen et al. ONCOLOGY RESEARCH
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
- (2015) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Proteomic Profiling of Paclitaxel Treated Cells Identifies a Novel Mechanism of Drug Resistance Mediated by PDCD4
- (2015) Hui Xu et al. JOURNAL OF PROTEOME RESEARCH
- Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
- (2015) H. P. Soares et al. MOLECULAR CANCER THERAPEUTICS
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway
- (2015) Azadeh Cheraghchi-Bashi et al. Oncotarget
- MEK and PI3K inhibition in solid tumors: rationale and evidence to date
- (2015) E. Jokinen et al. Therapeutic Advances in Medical Oncology
- Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer
- (2015) Sreedhar Venkannagari et al. Oncotarget
- DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance
- (2015) Euan A. Stronach et al. NEOPLASIA
- GDC-0980-induced apoptosis is enhanced by autophagy inhibition in human pancreatic cancer cells
- (2014) Jian-ying Tang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition
- (2014) H Hamidi et al. BRITISH JOURNAL OF CANCER
- Genetic Progression of Pancreatic Cancer
- (2014) Robert W. Cowan et al. CANCER JOURNAL
- PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced
- (2014) Abdelghani Jebahi et al. CANCER LETTERS
- Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
- (2014) R. Dienstmann et al. MOLECULAR CANCER THERAPEUTICS
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Inflammation and MiR-21 Pathways Functionally Interact to Downregulate PDCD4 in Colorectal Cancer
- (2014) Oliver Peacock et al. PLoS One
- Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer
- (2014) Todd M. Pitts et al. PLoS One
- Tumor suppressor genePDCD4negatively regulates autophagy by inhibiting the expression of autophagy-related geneATG5
- (2013) Xingguo Song et al. Autophagy
- Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers
- (2013) Sovan Sarkar BIOCHEMICAL SOCIETY TRANSACTIONS
- mTOR-dependent transcriptional repression of Pdcd4 tumor suppressor in lung cancer cells
- (2013) P.N. Vikhreva et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
- (2013) Carolyn D. Britten CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Control of a tumor suppressor PDCD4: Degradation mechanisms of the protein in hepatocellular carcinoma cells
- (2013) Sachiko Matsuhashi et al. CELLULAR SIGNALLING
- Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
- (2013) Karen E. Sheppard et al. EUROPEAN JOURNAL OF CANCER
- Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
- (2013) N. Tan et al. MOLECULAR CANCER THERAPEUTICS
- A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
- (2013) F. Abulwerdi et al. MOLECULAR CANCER THERAPEUTICS
- Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
- (2013) Jiri Polivka et al. PHARMACOLOGY & THERAPEUTICS
- Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models
- (2013) Hua Zhong et al. PLoS One
- Downregulation of programmed cell death 4 (PDCD4) in tumorigenesis and progression of human digestive tract cancers
- (2013) Gang Ma et al. TUMOR BIOLOGY
- mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
- (2013) A. C. Faber et al. Cancer Discovery
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- Tumour Suppressive Function and Modulation of Programmed Cell Death 4 (PDCD4) in Ovarian Cancer
- (2012) Na Wei et al. PLoS One
- A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
- (2012) Eric A. Collisson et al. Cancer Discovery
- Protein Arginine Methyltransferase 5 Accelerates Tumor Growth by Arginine Methylation of the Tumor Suppressor Programmed Cell Death 4
- (2011) M. A. Powers et al. CANCER RESEARCH
- Loss of programmed cell death 4 induces apoptosis by promoting the translation of procaspase-3 mRNA
- (2011) K Eto et al. CELL DEATH AND DIFFERENTIATION
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
- (2011) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
- (2011) Bert H. O'Neil et al. JOURNAL OF CLINICAL ONCOLOGY
- Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma
- (2011) Olga K. Mirzoeva et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines
- (2011) Wolfgang Glienke et al. TUMOR BIOLOGY
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
- (2010) E. B. Haura et al. CLINICAL CANCER RESEARCH
- Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor
- (2010) Aranapakam M. Venkatesan et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
- (2010) John D. Hainsworth et al. Journal of Thoracic Oncology
- Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells
- (2010) S. Huang et al. MOLECULAR CANCER THERAPEUTICS
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
- (2009) Na Wei et al. Molecular Cancer
- The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
- (2008) Stephen D. Barrett et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now